Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Kelly Pendergrass"'
Autor:
Brooke R. Daniel, Sharon A. Goble, Mark Keaton, Yvonne Manalo, Linda D. Bosserman, Denise A. Yardley, Martin J. Bury, David Drosick, Victor M. Priego, Howard A. Burris, Donald S. Gravenor, Robyn R. Young, Adam Brufsky, Fred J. Kudrik, Janice F. Eakle, William N. Harwin, Caryn Silver, Roger Inhorn, Jeffrey A. Bubis, John D. Hainsworth, Gladys Rodriguez, Edward Arrowsmith, Kelly Pendergrass
Publikováno v:
Breast Cancer Research and Treatment. 164:649-658
Ixabepilone is a microtubule stabilizer with activity in taxane-refractory metastatic breast cancer and low susceptibility to taxane-resistance mechanisms including multidrug-resistant phenotypes and high β-III tubulin expression. Since these resist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6962d6896792a1aa3aea5aa9da1eb20b
https://doi.org/10.1007/s10549-017-4285-6
https://doi.org/10.1007/s10549-017-4285-6
Autor:
Rustem Khasanov, Kelly Pendergrass, Luca Malorni, Yuri Rukazenkov, Iya Smirnova, Angelo Di Leo, Igor Bondarenko, Miguel Martin, Jose Luiz Pedrini, Sally Garnett, Lubos Petruzelka, Didier Verhoeven, Guy Jerusalem, Mikhail Lichinitser, Roberto Torres
Publikováno v:
JNCI Journal of the National Cancer Institute
Fulvestrant is a pure estrogen receptor (ER) antagonist devoid of the agonistic properties displayed by tamoxifen in some tissues (1–4). After phase III studies, which demonstrated similar efficacy and an acceptable safety profile for fulvestrant 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d147a7baf45412c9cf9646bf8af15fe
https://doi.org/10.1093/jnci/djw234
https://doi.org/10.1093/jnci/djw234
Autor:
Lubos Petruzelka, Miguel Martin, Guy Jerusalem, Sally Garnett, Rustem Khasanov, Mikhail Lichinitser, Kelly Pendergrass, Angelo Di Leo, Roberto Torres, Igor Bondarenko, Justin P.O. Lindemann, Iva Smirnova, Jose Luiz Pedrini, Didier Verhoeven
Publikováno v:
Breast Cancer Research and Treatment
Comparisons of duration of response (DoR) and duration of clinical benefit (DoCB) within clinical trials are prone to biases. To address these biases, we used new methodology to prospectively analyze expected DoR and expected DoCB. Objective response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4920540584ac264e8dd17bee4a659b1e
https://doi.org/10.1007/s10549-012-2395-8
https://doi.org/10.1007/s10549-012-2395-8
Autor:
Ranjana H. Advani, Eric D. Jacobsen, Kelly Pendergrass, Vanessa Bolejack, Nelida Sjak-Shie, Rami S. Komrokji, Andre Goy, Mitchell R. Smith, Francine M. Foss
Publikováno v:
Leukemia & Lymphoma. 54:1373-1379
This phase II study to determine the safety and efficacy of denileukin diftitox (DD) and cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) enrolled patients with newly diagnosed peripheral T-cell lymphoma (PTCL). Forty-nine received DD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::868c13ab22545d42a138808a64ab7237
https://doi.org/10.3109/10428194.2012.742521
https://doi.org/10.3109/10428194.2012.742521
Autor:
Tanja Trarbach, Bee Lian Chen, David J. Kerr, D. Laurent, H. J. Lenz, Kelly Pendergrass, Pierre Major, E. Van Cutsem, Christian Jacques, J.-Y. Douillard
3529 Background: PTK/ZK is an oral, antiangiogenic inhibitor of tyrosine kinase signaling of all known vascular endothelial growth factor receptors (VEGFR). PTK/ZK in combination with FOLFOX4 has been investigated in first line (CONFIRM 1[C1]) and se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75242fc5ec0f5146b2a1c39fc43d14a1
https://ora.ox.ac.uk/objects/uuid:ae2d9fae-f518-4fe2-9291-538477bf4628
https://ora.ox.ac.uk/objects/uuid:ae2d9fae-f518-4fe2-9291-538477bf4628
Autor:
György Bodoky, Tanja Trarbach, Kelly Pendergrass, Dirk Laurent, J. Randolph Hecht, David Lebwohl, Katherine Lloyd-Salvant, Elke Jäger, Pierre Major, Bee Lian Chen, Tarja Jalava, John D. Hainsworth, Gerold Meinhardt, Robert A. Wolff, David J. Kerr, William Berg
Publikováno v:
Journal of Clinical Oncology. 29:1997-2003
Purpose PTK787/ZK 222584 (PTK/ZK; vatalanib), an orally active, multitargeted angiogenesis inhibitor, has shown tolerability and promising activity in early-phase studies, which led to a phase III trial in combination with oxaliplatin, fluorouracil,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca0f0cd51d3f0933f7b6a29c1a679600
https://doi.org/10.1200/jco.2010.29.4496
https://doi.org/10.1200/jco.2010.29.4496
Autor:
Guy Jerusalem, Lubos Petruzelka, Miguel Martin, Jose Luiz Pedrini, Francisco Sapunar, Igor Bondarenko, Angelo Di Leo, Kelly Pendergrass, Didier Verhoeven, Sally Garnett, Roberto Torres, Mikhail Lichinitser, Iya Smirnova, Justin P.O. Lindemann, Rustem Khasanov
Publikováno v:
Journal of Clinical Oncology. 28:4594-4600
Purpose We compared fulvestrant 500 mg regimen with the approved dose of fulvestrant 250 mg per month for treatment of postmenopausal women with estrogen receptor–positive advanced breast cancer who experienced progression after prior endocrine the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63bd510e255097e9aac64f8de3affa4a
https://doi.org/10.1200/jco.2010.28.8415
https://doi.org/10.1200/jco.2010.28.8415
Autor:
Joe McIntosh, Kelly Pendergrass, James B. Bussel, David J. Kuter, Craig M. Kessler, Shande Tang, Adam Cuker, Louis M. Aledort
Publikováno v:
Blood. 123(25)
Stimulation of platelet production by thrombopoietin-receptor agonists (TPO-RAs) is an effective second-line treatment in immune thrombocytopenia (ITP). This 28-day phase 2 study assigned subjects with ITP of ≥3 months to once-daily oral avatrombop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7477da96e3e6fe7ac497ec67a17056b
https://pubmed.ncbi.nlm.nih.gov/24802775
https://pubmed.ncbi.nlm.nih.gov/24802775
Autor:
Kelly Pendergrass, Alexandra D. Carides, Barry J. Gertz, Hedy L. Kindler, Thomas H. Grote, Steven M. Grunberg, Mark G. Kris, Rudolph M. Navari, Ali Khojasteh, Paul J. Hesketh, Richard J. Gralla, Rick R. Reinhardt
Publikováno v:
New England Journal of Medicine. 340:190-195
Background The localization of substance P in brain-stem regions associated with vomiting, and the results of studies in ferrets, led us to postulate that a neurokinin-1–receptor antagonist would be an antiemetic in patients receiving anticancer ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::702cbcbdc639518c5c9c26cf6fe8d5b2
https://doi.org/10.1056/nejm199901213400304
https://doi.org/10.1056/nejm199901213400304
Autor:
Enrique Velez-Garcia, Richard A. Gams, Darcy V. Spicer, Ajit Desai, Sandra M. Swain, Joseph R. Bianchine, James L. Speyer, Steven Weisberg, Abraham Mittelman, Fredrick S. Whaley, Martin York, Stephen E. Jones, Scott Wadler, Kelly Pendergrass, Sandeep K. Reddy, Miriam C. Gerber, Charles L. Vogel, Michael S. Ewer
Publikováno v:
Europe PubMed Central
Scopus-Elsevier
Scopus-Elsevier
PURPOSE To determine the cardioprotective effect of dexrazoxane (DZR) used in a doxorubicin-based combination therapy in advanced breast cancer. PATIENTS AND METHODS Between November 1988 and January 1991, 534 patients with advanced breast cancer wer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f5937929f8ed4d6fce90cd4d9742a6e
https://doi.org/10.1200/jco.1997.15.4.1318
https://doi.org/10.1200/jco.1997.15.4.1318